Home › Biodesix, University of Colorado Partner on Lung Cancer Assay

Biodesix, University of Colorado Partner on Lung Cancer Assay

Jan 31, 2018

NEW YORK (GenomeWeb) – Biodesix announced today that it has partnered with the University of Colorado Cancer Center to develop a blood-based assay designed to help identify non-small cell lung cancer (NSCLC) patients likely to respond to certain immunotherapies.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Nov
05
Featured Webinar

Overcoming Challenges in Solid Tumor Testing with Advanced AI

Sponsored by
Sophia Genetics

With the Next Generation Sequencing (NGS), genomes sequencing has been democratized over the last decades with the detection of genomic alterations, thus replacing Sanger sequencing.

What's Popular?

In Molecular Diagnostics

  1. Thermo Fisher Scientific Gets CE-IVD Mark for NGS Cancer Test

  2. Roche Diagnostics' Revenues Grow 6 Percent in First Nine Months of 2018

  3. FDA Approves Myriad Genetics BRCA CDx With Pfizer's Metastatic Breast Cancer Drug

  4. Abbott Q3 Dx Business Grows 43 Percent

  5. At ASHG, Singlera Genomics Presents Data on Cell-Free DNA Methylation Test for Early Cancer Detection

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2018 GenomeWeb LLC.  All Rights Reserved.